XORTX Therapeutics Receives ISS Support Ahead of Upcoming Meeting
CALGARY, Alberta – XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) is excited to announce that it has received a significant endorsement from Institutional Shareholder Services Inc. (ISS), an independent proxy advisory firm. As the company gears up for its important Annual and Special Meeting of Shareholders scheduled for September 12, 2024, ISS has strongly encouraged shareholders to vote in favor of all the proposed resolutions.
The Importance of Shareholder Involvement
XORTX's leadership is urging all shareholders to understand the significance of their votes. Regardless of how many shares they own, participating in this vote is vital for ensuring that the collective voice of shareholders is heard. The deadline for proxy voting is fast approaching, set for 10:00 am Calgary time on September 10, 2024.
Meeting Details
During the upcoming meeting, shareholders will deliberate on essential resolutions that will impact the company's future direction. The meeting is set to begin at 10:00 am on September 12, 2024, at the corporate headquarters located at 3710 – 33rd Street NW, Calgary. Shareholders are encouraged to review all relevant documentation and stay informed about the meeting agenda.
Voting Support and Contact Information
For those who require assistance or clarification regarding the agenda items or the voting process, XORTX has appointed Laurel Hill Advisory Group as their proxy solicitation agent. They can be reached toll-free within North America at 1-877-452-7184 or via email.
About XORTX Therapeutics
XORTX Therapeutics is leading the way in developing innovative therapies aimed at addressing progressive kidney disease. The company is advancing two primary programs: the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD) and the XRx-101 program, which focuses on acute kidney injuries related to viral infections. Additionally, XORTX is working on XRx-225, targeting Type 2 Diabetic Nephropathy, thereby paving the way for groundbreaking treatment options for chronic health issues.
Dedication to Patient Health
At XORTX, the mission is straightforward: to improve the lives of patients dealing with chronic kidney conditions. The emphasis on aberrant purine metabolism and xanthine oxidase inhibition highlights the company's commitment to tackling these significant health challenges with innovative therapies. XORTX is diligently progressing these promising treatments through clinical trials to make them available to healthcare professionals.
Frequently Asked Questions
What is the purpose of the upcoming meeting for XORTX shareholders?
The meeting is designed to discuss important resolutions that will influence the future of XORTX Therapeutics and to confirm the endorsement from ISS for these proposals.
Why is the ISS recommendation significant?
ISS offers independent perspectives on corporate governance and shareholder matters, which can greatly affect shareholder decisions and foster trust in the company's management.
How can shareholders make sure their voices are heard?
Shareholders need to cast their votes before the deadline to ensure their opinions and preferences regarding the proposed resolutions are officially acknowledged and taken into account.
What are the main initiatives of XORTX?
XORTX is dedicated to developing therapies for chronic kidney diseases, with key programs targeting ADPKD and acute kidney injury.
How can shareholders obtain more information about the meeting?
XORTX investors can reach out to Laurel Hill Advisory Group for assistance or visit the company’s website for comprehensive information and documentation related to the meeting.
